Previous 10 | Next 10 |
2023-04-28 10:54:53 ET The following slide deck was published by Biogen Inc. in conjunction with their 2023 Q1 earnings call. For further details see: Biogen Inc. 2023 Q1 - Results - Earnings Call Presentation
2023-04-28 09:00:26 ET Summary Advisory Committee meeting for Biogen's LEQEMBI is set for June 9. Prescription Drug User Fee Act action date is a month later on July 6. Another PDUFA date is August 5 for zuranolone in two indications. Shares of Biogen ( BIIB ) ha...
2023-04-27 07:37:27 ET Listen on the go! Subscribe to Wall Street Breakfast on Apple Podcasts and Spotify Meta ( META ) earnings call: Never mind the ad beat , here's the AI future (and present). Disney ( DIS ) sues Florida Gov. DeSantis after...
2023-04-26 16:05:11 ET Biogen ( NASDAQ: BIIB ) shares bounced back Wednesday after a top Medicare official said that the agency would cover the new Alzheimer's treatment Leqembi (lecanemab) in the event of full US FDA approval. Testifying before the House Subcommittee o...
2023-04-26 11:32:44 ET Eli Lilly ( NYSE: LLY ) is expected to report its Q1 2023 results before the opening bell on Thursday for a market on the lookout for updates on its pipeline led by Alzheimer’s candidate donanemab and weight loss agent tirzepatide. Amid waning deman...
2023-04-26 09:26:28 ET The European Union on Wednesday published a long-awaited set of proposals to overhaul the laws governing the region's pharmaceutical industry amid opposition from leading drugmakers. "Over the last decade, reports of medicines shortages, including of antibiotics, ...
FDA granted accelerated approval of QALSODY based on a reduction of neurofilament, a marker of neurodegeneration 1 Superoxide dismutase 1 ( SOD1 )-amyotrophic lateral sclerosis (ALS) is a devastating, uniformly fatal, 2 and ultra-rare genetic form of ALS 3-4 with approximate...
2023-04-25 13:46:35 ET The FDA announced Tuesday the approval of Qalsody (tofersen) developed by Biogen ( NASDAQ: BIIB ) and Ionis Pharmaceuticals ( IONS ) for certain patients with neurodegenerative disease amyotrophic lateral sclerosis (ALS). Specifically, the FDA has clea...
2023-04-25 12:37:13 ET Biogen Inc. (BIIB) Q1 2023 Earnings Conference Call April 25, 2023, 8:00 AM ET Company Participants Chuck Triano - Head of Investor Relations Christopher Viehbacher - President and Chief Executive Officer Priya Singhal - Head of Development...
2023-04-25 08:01:00 ET Biogen ( NASDAQ: BIIB ) stock is trading in the red premarket Tuesday after the company said it is discontinuing certain drug programs amid reporting its Q1 results, which beat estimates. Biogen said it will terminate its involvement in developing BI...
News, Short Squeeze, Breakout and More Instantly...
CAMBRIDGE, Mass., July 02, 2024 (GLOBE NEWSWIRE) -- Biogen Inc. (Nasdaq: BIIB) has completed the acquisition of Human Immunology Biosciences (HI-Bio™), a privately-held clinical-stage biotechnology company focused on targeted therapies for patients with severe immune-mediated diseases ...
TOKYO and CAMBRIDGE, Mass., June 27, 2024 (GLOBE NEWSWIRE) -- Eisai Co., Ltd. (Headquarters: Tokyo, CEO: Haruo Naito, “Eisai”) and Biogen Inc. (Nasdaq: BIIB, Corporate headquarters: Cambridge, Massachusetts, CEO: Christopher A. Viehbacher, “Biogen”) announced today tha...
NEW YORK, NY / ACCESSWIRE / June 12, 2024 / Leading law firm Bleichmar Fonti & Auld LLP announces the upcoming July 22, 2024, deadline in the Biogen Inc. (Nasdaq:BIIB) Securities Class Action Lawsuit. If you invested in Biogen, you are encouraged to obtain additional information by visiting ...